14 active not recruiting, 14 completed, 4 recruiting, 3 terminated. 23 Phase 2, 7 Phase 1, 6 Phase 3, 1 Phase 4.
Follow Jnj-56021927: new trials by email Literature Review of Jnj-56021927 trials Research Report on Jnj-56021927
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial Abiraterone, Apalutamide, Biospecimen Collection - Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer | Phase 2 | Recruiting | Mayo Clinic | 532 | 2024-06-03 | 2026-07-20 |
| Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study Apalutamide, Biopsy, Biospecimen Collection - Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Terminated | University of Washington | 8 | 2024-05-23 | 2026-10-19 |
| Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial Apalutamide, Biospecimen Collection, Computed Tomography - Prostate Adenocarcinoma, Stage II Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 95 | 2024-03-28 | 2026-07-17 |
| Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer Abiraterone Acetate, Antiandrogen Therapy, Apalutamide - Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8 | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 200 | 2021-08-05 | 2026-06-23 |
| Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland Apalutamide, Biospecimen Collection, Quality-of-Life Assessment - Localized Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 34 | 2021-07-23 | 2026-06-25 |
| Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer Abiraterone Acetate, Apalutamide, Leuprolide Acetate - Metastatic Prostate Adenocarcinoma, Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation | Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 28 | 2021-03-17 | 2026-02-05 |
| Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial Apalutamide, Bicalutamide, Biospecimen Collection - Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8 | Phase 3 | Active not recruiting | NRG Oncology | 2753 | 2021-01-21 | 2026-08-17 |
| Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer Apalutamide, IHT - Prostate Cancer | Phase 2 | Withdrawn | The University of Texas Health Science Center, Houston | 2020-12-01 | 2020-02-27 | |
| Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study Apalutamide, Degarelix, Leuprolide Acetate - Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2020-11-24 | 2021-01-20 | |
| A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer Radiotherapy, LHRHa, Apalutamide - Prostatic Neoplasms | Phase 3 | Active not recruiting | Janssen Pharmaceutica N.V., Belgium | 691 | 2020-11-12 | 2026-09-25 |
| Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography - Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 804 | 2020-10-08 | 2026-08-19 |
| A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases Apalutamide, ADT, Relugolix - Prostatic Neoplasms | Phase 2 | Completed | Janssen Research & Development, LLC | 108 | 2020-08-19 | 2026-04-21 |
| Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer Abiraterone Acetate, Antiandrogen Therapy, Apalutamide - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Active not recruiting | OHSU Knight Cancer Institute | 7 | 2020-05-11 | 2026-07-15 |
| Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial Apalutamide, Biospecimen Collection, Bone Scan - Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8 | Phase 3 | Active not recruiting | NRG Oncology | 586 | 2020-04-16 | 2026-08-17 |
| A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma Apalutamide, GnRH Agonist - Salivary Gland Neoplasms | Phase 2 | Active not recruiting | Janssen Pharmaceutical K.K. | 31 | 2020-04-07 | 2026-09-25 |
| A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC) Apalutamide, Placebo, Androgen-deprivation Therapy (ADT) - Prostatic Neoplasms | Phase 4 | Completed | Janssen Research & Development, LLC | 75 | 2019-12-17 | 2026-07-30 |
| A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function Apalutamide - Hepatic Impairment | Phase 1 | Completed | Janssen Research & Development, LLC | 18 | 2019-11-07 | 2025-07-20 |
| Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer Abiraterone Acetate, Apalutamide, Prednisone - Metastatic Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 60 | 2019-07-22 | 2026-10-07 |
| A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy Apalutamide, Androgen Deprivation Therapy (ADT), Placebo - Prostatic Neoplasms | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 2517 | 2019-06-11 | 2026-09-25 |
| A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer Apalutamide - Prostatic Neoplasms | Phase 1 | Active not recruiting | Janssen Research & Development, LLC | 19 | 2018-08-31 | 2026-09-25 |
Showing 20 of 38. Sign in to see all of them.
Prostatic Neoplasms (32) · Prostatic Neoplasms, Castration-Resistant (2) · Bulbo-Spinal Atrophy, X-Linked (1) · Salivary Gland Neoplasms (1)
M.D. Anderson Cancer Center (7) · Janssen Research & Development, LLC (6) · Aragon Pharmaceuticals, Inc. (5) · NRG Oncology (3) · University of Washington (3) · Janssen Pharmaceutical K.K. (2) · Jonsson Comprehensive Cancer Center (2) · Andrew J. Armstrong, MD (1) · CCTU- Cancer Theme (1) · Dana-Farber Cancer Institute (1) · ECOG-ACRIN Cancer Research Group (1) · Janssen Pharmaceutica N.V., Belgium (1) · Mayo Clinic (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1)
United States (32) · Canada (7) · Brazil (4) · Japan (4) · Russia (4) · Spain (4) · United Kingdom (4) · Australia (3) · China (3) · Czechia (3) · Germany (3) · Italy (3) · Mexico (3) · Netherlands (3) · Poland (3)
Amar Kishan (2) · Michael Schweizer (2) · Ana Aparicio (1) · Bagi Jana, MD (1) · Christopher Logothetis (1) · Eleni Efstathiou (1) · Felix Y Feng (1) · Jacob J. Orme, MD, PhD (1) · John W Davis (1) · Juan Chipollini (1)
PMID 38421243, PMID 32878613, PMID 31150574, PMID 31446511, PMID 31578173, PMID 33683939, PMID 33914595, PMID 34039013, PMID 36082554, PMID 36472728, PMID 37708629, PMID 37951974, PMID 38161319, PMID 38421252, PMID 38494380, PMID 38940282, PMID 39058790, PMID 39074346, PMID 39088398, PMID 39163505, PMID 41202201, PMID 42117295, PMID 42223077, PMID 42616151, PMID 42728112
U10CA180868 (3), 2017 (2), 2018 (2), 2023 (2), P30CA015704 (2), 2014 (1), 2015 (1), 2019 (1), P30CA023074 (1), R01CA286127 (1), R01CA300454 (1), U10CA180820 (1), UG1CA242596 (1)